Mass spectrometry technology contributed to the advancement of cancer immunotherapyDiscovering a Biomarker for Predicting the Clinical Outcome of Cancer Patients treated with a New Combination Immunotherapy in a Phase I Clinical Trial Conducted by Providence Cancer Institute, USA